Research programme: protein therapeutics - Intas Biopharmaceuticals/Viropro
Latest Information Update: 30 Sep 2011
At a glance
- Originator Intas Biopharmaceuticals; Viropro
- Class Proteins
- Mechanism of Action Protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 11 Oct 2007 Preclinical trials in Undefined indication in India (Parenteral)
- 11 Oct 2007 Preclinical trials in Undefined indication in Canada (Parenteral)